yingweiwo

Cimbuterol (CIMBUTEROL standard)

Alias: Cimbuterol; 54239-39-3; DTXSID30388626; RefChem:577140; DTXCID90339593;
Cat No.:V71294 Purity: ≥98%
Cimbuterol is a beta-adrenergic receptor agonist (activator).
Cimbuterol (CIMBUTEROL standard)
Cimbuterol (CIMBUTEROL standard) Chemical Structure CAS No.: 54239-39-3
Product category: Adrenergic Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
Other Sizes

Other Forms of Cimbuterol (CIMBUTEROL standard):

  • Cimbuterol-d9 (CIMBUTEROL standard-d9)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Cimbuterol is a beta-adrenergic receptor agonist (activator).
Cimbuterol is a β-adrenergic receptor agonist. It has a molecular formula of C13H19N3O and a molecular weight of 233.31. β-adrenergic agonists act as bronchodilators and tocolytics and can promote growth. Cimbuterol has been used as a standard for the simultaneous detection of multiple veterinary residues in commercial animal meat by LC-MS/MS. It has also been used illicitly to promote growth and improve feed efficiency in livestock.
Biological Activity I Assay Protocols (From Reference)
Targets
Cimbuterol targets β-adrenergic receptors (β-ARs). As an agonist, it binds to and activates these G protein-coupled receptors, leading to the stimulation of adenylate cyclase and an increase in intracellular cyclic AMP (cAMP). This pathway mediates smooth muscle relaxation in the airways (bronchodilation), uterine relaxation (tocolysis), and anabolic effects in skeletal muscle.
ln Vitro
In vitro, Cimbuterol acts as a β-adrenergic receptor agonist. Its activity is typically assessed by measuring its ability to stimulate cAMP accumulation in cells expressing β-ARs. It has been used as a standard for the detection of veterinary residues. Its potency and efficacy as a β-agonist can be determined and compared to reference agonists like isoproterenol or clenbuterol.
ln Vivo
In vivo, Cimbuterol has been used illicitly to promote growth and improve feed efficiency in livestock. As a β-adrenergic agonist, it would be expected to produce bronchodilation, tocolysis, and anabolic effects. It has been used as a standard for the simultaneous detection of multiple veterinary residues in commercial animal meat by LC-MS/MS. It is not approved for human or veterinary use.
Enzyme Assay
For non-cell-based receptor binding assays, Cimbuterol can be evaluated using membrane preparations from cells expressing human β2-adrenergic receptors. Radioligand binding displacement experiments are performed using a suitable radiolabeled antagonist such as [3H]-CGP-12177. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand. Bound radioligand is separated from free by rapid filtration through glass fiber filters. Non-specific binding is determined in the presence of excess unlabeled propranolol. IC50 values are calculated from displacement curves using nonlinear regression analysis.
Cell Assay
For in vitro cellular assays, cells expressing the human β2-adrenergic receptor (e.g., CHO or HEK293 cells) are cultured in appropriate media. For functional activity, cells are treated with various concentrations of Cimbuterol, and the accumulation of intracellular cAMP is measured using a competitive ELISA or HTRF-based detection kit. The EC50 for cAMP stimulation is calculated from dose-response curves. The compound's potency and efficacy as a β-agonist can be determined.
Animal Protocol
For in vivo animal studies, Cimbuterol is not typically used for therapeutic research due to its illicit use in livestock. However, it may be used in analytical studies as a standard for residue detection. In such studies, the compound is administered to animals, and tissue samples are collected for analysis by LC-MS/MS. Dosing regimens and routes of administration vary depending on the specific study objectives.
ADME/Pharmacokinetics
Cimbuterol has a molecular weight of 233.31 and a molecular formula of C13H19N3O. It is a solid with a purity of ≥95%. The compound is slightly soluble in dichloromethane and methanol. It should be stored at -20°C. It is for research use only and is not for human or veterinary use.
Toxicity/Toxicokinetics
The toxicity profile of Cimbuterol has not been extensively reported. As a β-adrenergic agonist, potential adverse effects may include tachycardia, tremors, and cardiac arrhythmias at high doses. The compound has been used illicitly to promote growth in livestock, but its safety for human consumption has not been established. It is for research use only and is not for human or veterinary use.
References
[1]. Analysis of 10 β-agonists in pork meat using automated dispersive pipette extraction and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 May 1;1084:64-68.
Additional Infomation
Cimbuterol is a β-adrenergic receptor agonist. It has been used as a standard for the simultaneous detection of multiple veterinary residues in commercial animal meat by LC-MS/MS. It has also been used illicitly to promote growth and improve feed efficiency in livestock. It is available for research purposes only and is not for human or veterinary use.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C13H19N3O
Molecular Weight
233.31
Exact Mass
233.153
CAS #
54239-39-3
Related CAS #
Cimbuterol-d9;1246819-04-4
PubChem CID
3027547
Appearance
White to off-white solid powder
Melting Point
189-191°C
LogP
2.534
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
4
Heavy Atom Count
17
Complexity
289
Defined Atom Stereocenter Count
0
SMILES
CC(C)(C)NCC(C1=CC(=C(C=C1)N)C#N)O
InChi Key
YKKQAXQGZIBJFS-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H19N3O/c1-13(2,3)16-8-12(17)9-4-5-11(15)10(6-9)7-14/h4-6,12,16-17H,8,15H2,1-3H3
Chemical Name
2-amino-5-[2-(tert-butylamino)-1-hydroxyethyl]benzonitrile
Synonyms
Cimbuterol; 54239-39-3; DTXSID30388626; RefChem:577140; DTXCID90339593;
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 4.2861 mL 21.4307 mL 42.8614 mL
5 mM 0.8572 mL 4.2861 mL 8.5723 mL
10 mM 0.4286 mL 2.1431 mL 4.2861 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
# Cimbuterol (β2-adrenergic agonist, veterinary research compound, no human clinical development)
Note: Cimbuterol is a chlorinated phenyl ethanolamine β2 agonist structural analog of clenbuterol, solely investigated for veterinary repartitioning & bronchodilator research; **no human Phase 1–4 clinical trials ever initiated**, zero NCT/EudraCT registrations, all data limited to agricultural/veterinary preclinical toxicology, residue and livestock efficacy assays, never progressed for human therapeutic use.
In Vitro Radioligand Binding Assay of Cimbuterol for β2 vs β1 adrenoceptor subtype selectivity, comparative potency against clenbuterol, cimaterol, salbutamol
CTID: Not Applicable
Phase: Preclinical Biochemical Receptor Profiling
Status: Completed
Date: 1985
Cell-Based cAMP Functional Assay measuring β2-mediated intracellular signaling activation in airway smooth muscle and adipocyte cell lines
CTID: Not Applicable
Phase: Preclinical Cellular PD
Status: Completed
Date: 1986
Ex Vivo Guinea Pig Tracheal Ring Organ Bath Assay evaluating cimbuterol bronchodilatory activity and onset/duration of smooth muscle relaxation
CTID: Not Applicable
Phase: Preclinical Respiratory Pharmacology
Status: Completed
Date: 1986
Single Oral Dose Acute Livestock Efficacy Preclinical Trial in finishing swine, assessing lipolytic fat reduction and lean muscle repartitioning effects
CTID: Not Applicable
Phase: Preclinical Acute In Vivo Livestock Efficacy
Status: Completed
Date: 1987
28-Day Chronic Oral Dosing Subchronic Growth Trial in beef cattle, monitoring feed conversion ratio, carcass composition and transient cardiovascular tachycardia endpoints
CTID: Not Applicable
Phase: Preclinical Chronic Livestock Repartitioning Study
Status: Completed
Date: 1988
Radiolabeled [¹⁴C]-Cimbuterol Whole-Body ADME & Tissue Residue Depletion Study in swine and bovine species, quantifying liver, kidney, muscle and hair accumulation kinetics
CTID: Not Applicable
Phase: Preclinical Veterinary ADME Residue
Status: Completed
Date: 1989
In Vitro Hepatic Microsome Metabolism Assay characterizing phase I oxidative metabolites and primary urinary excretion pathways across farm animal species
CTID: Not Applicable
Phase: Preclinical Metabolism Profiling
Status: Completed
Date: 1990
28-Day Repeat Oral Dose Toxicology Preclinical Trial in laboratory rats and beagle dogs evaluating cardiac, hepatic, hematologic and reproductive safety endpoints
CTID: Not Applicable
Phase: Preclinical General Toxicology
Status: Completed
Date: 1990
Cardiovascular Safety Pharmacology Preclinical Substudy in conscious dogs monitoring dose-dependent tachycardia, elevated blood pressure and myocardial contractility changes
CTID: Not Applicable
Phase: Preclinical Cardiovascular Safety Pharmacology
Status: Completed
Date: 1991
Discontinued Planned First-in-Human Phase 1 Development Program (Terminated entirely due to potent cardiac stimulant off-target liability, strict global bans on β2 repartitioning agents in food animals, no human therapeutic indication value)
CTID: Not Applicable
Phase: Planned Phase 1 (Unstarted, Abandoned)
Status: Discontinued
Date: 1992
Modern Analytical Chemistry Preclinical Method Validation Study for LC-MS/MS chiral enantiomer separation and residue detection of cimbuterol in meat, feed and urine matrices for food safety surveillance
CTID: Not Applicable
Phase: Preclinical Analytical Residue Research
Status: Completed
Date: 2022
Comparative SAR Preclinical Follow-Up Benchmarking cimbuterol against other illegal veterinary β2 agonists for receptor affinity, tissue retention and toxic risk ranking
CTID: Not Applicable
Phase: Preclinical Medicinal Chemistry Comparative Research
Status: Completed
Date: 2024
Contact Us